SK BIOSCIENCE CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57,900 KRW | -2.85% |
|
-2.53% | -19.58% |
| May. 03 | SK Bioscience's Attributable Loss Narrows in Q1 | MT |
| Mar. 28 | SK Bioscience Signs Deal with Sanofi for Five Vaccine Types | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 17,212,500 | 5,643,627 | 5,528,451 | 4,448,327 | - | - |
| Enterprise Value (EV) 2 | 17,126 | 4,208 | 4,254 | 3,206 | 3,785 | 3,858 |
| P/E ratio | 46.8 x | 46.2 x | 248 x | -119 x | -277 x | 130 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 18.5 x | 12.4 x | 15 x | 18.4 x | 13.7 x | 14.4 x |
| EV / Revenue | 18.4 x | 9.21 x | 11.5 x | 13.3 x | 11.7 x | 12.5 x |
| EV / EBITDA | 34.7 x | 29.6 x | 187 x | -48.6 x | 454 x | -96.4 x |
| EV / FCF | 34.7 x | -21.3 x | -302 x | -291 x | -32.1 x | -772 x |
| FCF Yield | 2.88% | -4.7% | -0.33% | -0.34% | -3.11% | -0.13% |
| Price to Book | 10.4 x | 3.24 x | 3.24 x | 2.65 x | 2.68 x | 2.73 x |
| Nbr of stocks (in thousands) | 76,500 | 76,784 | 76,784 | 76,828 | - | - |
| Reference price 3 | 225,000 | 73,500 | 72,000 | 57,900 | 57,900 | 57,900 |
| Announcement Date | 2/7/22 | 2/8/23 | 2/1/24 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 183.2 | 225.6 | 929 | 456.7 | 369.5 | 242 | 324.8 | 308 |
| EBITDA 1 | - | - | 493 | 142.3 | 22.78 | -66 | 8.333 | -40 |
| EBIT 1 | - | 37.71 | 474.2 | 115 | -11.99 | -63.22 | -45.23 | -92.39 |
| Operating Margin | - | 16.71% | 51.05% | 25.18% | -3.24% | -26.13% | -13.93% | -29.99% |
| Earnings before Tax (EBT) 1 | - | - | 471.1 | 141.7 | 7.327 | -38.86 | -14.02 | 47.17 |
| Net income 1 | - | - | 355.1 | 122.5 | 22.32 | -37.41 | -16.21 | 33.93 |
| Net margin | - | - | 38.23% | 26.81% | 6.04% | -15.46% | -4.99% | 11.01% |
| EPS 2 | 6,933 | - | 4,810 | 1,590 | 290.0 | -487.3 | -209.0 | 443.8 |
| Free Cash Flow 3 | - | - | 493,686 | -197,951 | -14,095 | -11,000 | -117,780 | -5,000 |
| FCF margin | - | - | 53,141.65% | -43,341.33% | -3,814.51% | -4,546.18% | -36,263.7% | -1,623.17% |
| FCF Conversion (EBITDA) | - | - | 100,140.23% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | 139,011.89% | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/23/21 | 2/7/22 | 2/8/23 | 2/1/24 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 257.3 | 220.8 | 450.9 | 87.09 | 138.3 | 91.05 | 140.3 | 20.6 | 26.48 | 231.8 | 90.6 | 22.27 | 54.15 | 89 | 67 |
| EBITDA | - | - | - | - | 67.63 | - | 16.56 | -20.92 | - | - | - | - | - | - | - |
| EBIT 1 | - | 100.4 | 253.9 | 23.75 | 61.19 | 21.36 | 8.714 | -29.19 | -35.31 | 60.94 | -8.427 | -28.1 | -18.35 | -1.25 | -6.4 |
| Operating Margin | - | 45.47% | 56.32% | 27.27% | 44.25% | 23.46% | 6.21% | -141.71% | -133.35% | 26.29% | -9.3% | -126.18% | -33.89% | -1.4% | -9.55% |
| Earnings before Tax (EBT) 1 | - | 96.57 | 251.6 | 32.76 | 55.34 | 23.18 | 30.46 | -25.66 | -29.24 | 58.62 | 3.605 | -19.81 | -18.4 | -1 | -4.7 |
| Net income 1 | - | 76.44 | 184 | 27.81 | 46.13 | 20.78 | 27.74 | -14.27 | -15.98 | 48.39 | 4.17 | -13.72 | -14 | -0.7 | -3.6 |
| Net margin | - | 34.61% | 40.8% | 31.93% | 33.36% | 22.82% | 19.77% | -69.27% | -60.34% | 20.87% | 4.6% | -61.6% | -25.85% | -0.79% | -5.37% |
| EPS | 1,342 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/12/21 | 10/29/21 | 2/7/22 | 4/29/22 | 7/29/22 | 10/31/22 | 2/8/23 | 4/27/23 | 7/28/23 | 10/26/23 | 2/1/24 | 5/2/24 | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 86.4 | 1,435 | 1,274 | 1,242 | 663 | 590 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 2 | - | - | 493,686 | -197,951 | -14,095 | -11,000 | -117,780 | -5,000 |
| ROE (net income / shareholders' equity) | - | - | 38.1% | 7.33% | 1.3% | -2.13% | -1.44% | -0.19% |
| ROA (Net income/ Total Assets) | - | - | 26.6% | 5.76% | 1.12% | -3.4% | -1.92% | -0.9% |
| Assets 1 | - | - | 1,336 | 2,126 | 1,997 | 1,100 | 844.1 | -3,770 |
| Book Value Per Share 3 | - | - | 21,689 | 22,703 | 22,190 | 21,874 | 21,583 | 21,239 |
| Cash Flow per Share 3 | - | - | 7,268 | -1,622 | 382.0 | 545.0 | 670.0 | 1,653 |
| Capex 1 | - | - | 42.9 | 73 | 43.4 | 284 | 171 | 20 |
| Capex / Sales | - | - | 4.62% | 15.98% | 11.76% | 117.31% | 52.7% | 6.49% |
| Announcement Date | 3/30/20 | 3/23/21 | 2/7/22 | 2/8/23 | 2/1/24 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
57,900
KRW
Average target price
58,000
KRW
Spread / Average Target
+0.17%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.58% | 3.37B | |
| -2.59% | 89.69B | |
| +2.50% | 41.34B | |
| -12.01% | 33.72B | |
| +62.74% | 26.11B | |
| -19.79% | 14.63B | |
| -8.58% | 12.84B | |
| -12.34% | 11.66B | |
| -43.92% | 11.52B | |
| +4.27% | 8.92B |
- Stock Market
- Equities
- A302440 Stock
- Financials SK bioscience Co.,Ltd.
